New Cancer Drug Is So Effective Against Tumors, the FDA Approved It Immediately

New Cancer Drug Is So Effective Against Tumors, the FDA Approved It Immediately – Yahoo

 

 

A small but significant new study is blowing experts away after it found that a particular cancer drug overwhelmingly helped shrink or eradicate tumors in patients whose cancer had resisted every other form of treatment.

The study, which was published in the journal Science, followed 86 patients who had advanced cancer of the pancreas, prostate, uterus, or bone. The patients were given pembrolizumab, which also goes by the brand name Keytruda, and the results were very promising. Sixty-six patients had tumors that shrank significantly and stabilized; among them were 18 patients whose tumors disappeared and haven’t returned.

The patients all carried genetic mutations that kept their cells from fixing damaged DNA. Pembrolizumab is known as a PD-1 blocker, an emerging type of immunotherapy drug that helps the immune system find cancer cells and attack tumors.

The PD-1 immunotherapy drug Keytruda. (Image: Merck)

The study was small, and there was no control group (i.e., a group that didn’t receive pembrolizumab that scientists could compare results against), but the results were so striking that the FDA has already approved pembrolizumab for patients whose cancer comes from this particular genetic abnormality.

 

Read more: New Cancer Drug Is So Effective Against Tumors, the FDA Approved It Immediately

 

 

FAIR USE STATEMENT
This site may contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. The Uncensored Report (“the site”) is making such material available in an effort to further understanding of political, social, economic, and scientific issues, etc. The site asserts this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law.

Please follow and like us:

Leave a Reply

Your email address will not be published. Required fields are marked *